Abstract | PURPOSE: Although the use of regimens with adjuvant taxanes is a standard approach in node-positive breast cancer, the use of taxanes in node-negative breast cancer is still controversial. In this search, we aimed to evaluate the data about the use of taxanes in high-risk node-negative patients. METHODS: Studies were retrieved by searching the Pubmed database. Randomized phase III studies on the use of regimens with adjuvant taxanes in early-stage breast cancer were screened and, among them, the studies that included node-negative patients were included in the evaluation. RESULTS: Data on the adjuvant use of taxanes in nodenegative patients were classified into 3 categories: a) studies that evaluated both node-positive and node-negative patients; b) meta-analyses on the use of adjuvant taxanes; and c) studies that included node-negative patients alone. The results of the studies that evaluated both node-positive and node-negative patients and the meta-analyses were evaluated according to the node-negative subgroup analyses. While two of these studies did not show difference in disease-free survival (DFS) for the node-negative subgroup, one study showed a difference in DFS. The only data for the adjuvant use of taxanes in only node-negative breast cancers belong to GEICAM 9805 study and, according to its results, docetaxel provided a difference in DFS in high-risk node-negative patients. CONCLUSION: Data about the adjuvant use of taxanes in node-negative patients are limited compared to the studies in which both node-positive and node-negative subgroups are evaluated. In the light of these studies, it is impossible to make a comment about the use of taxanes in node-negative patients. However, GEICAM 9805 study has shown positive results on DFS in high-risk node-negative breast cancer patients with adjuvant taxanes.
|
Authors | N Ozdemir, S Aksoy, N Zengin, K Altundag |
Journal | Journal of B.U.ON. : official journal of the Balkan Union of Oncology
(J BUON)
2012 Jan-Mar
Vol. 17
Issue 1
Pg. 27-32
ISSN: 1107-0625 [Print] Cyprus |
PMID | 22517689
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Breast Neoplasms
(drug therapy, mortality)
- Chemotherapy, Adjuvant
- Clinical Trials, Phase III as Topic
- Disease-Free Survival
- Female
- Humans
- Lymphatic Metastasis
- Meta-Analysis as Topic
- Taxoids
(therapeutic use)
|